{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Moleculin Biotech, Inc."},"Symbol":{"label":"Symbol","value":"MBRX"},"Address":{"label":"Address","value":"5300 MEMORIAL DRIVE,SUITE 950, HOUSTON, Texas, 77007, United States"},"Phone":{"label":"Phone","value":"+1 713 300-5160"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Moleculin Biotech Inc is a clinical-stage pharmaceutical company with a focus on the treatment of highly resistant cancers and viruses through the development of its drug candidates. The company has three core technologies: Annamycin which is a next-generation anthracycline; Immune/Transcription Modulators, of which WP1066 is a member; and Metabolism/Glycosylation Inhibitors, of which WP1122 is a member."},"CompanyUrl":{"label":"Company Url","value":"https://www.moleculin.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Donald H. Picker","title":"Chief Scientific Officer"},{"name":"John Paul Waymack","title":"Senior Chief Medical Officer"},{"name":"Sandra Leta Silberman","title":"Chief Medical Officer-New Products"},{"name":"Walter V. Klemp","title":"Chairman, President & Chief Executive Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}